Inflectra Becomes Australia's First Biosimilar MAb
This article was originally published in Scrip
Executive Summary
The Australian Therapeutic Goods Administration (TGA) has approved the country's first biosimilar monoclonal antibody – Hospira's Inflectra (infliximab), a version of Johnson & Johnson's Remicade.